Monte Rosa Therapeutics (GLUE) Other Working Capital Changes (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Other Working Capital Changes of -$434000.0 for Q1 2026, down 53.36% year-over-year from -$930469.7 in Q1 2025, and down 45.64% quarter-over-quarter from -$298000.0 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$434000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 53.36% year-over-year to -$434000.0; the TTM figure through Mar 2026 stood at -$1.2 million (down 6.03% YoY), while the FY2025 annual figure was -$1.1 million, up 19.96% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$434000.0, down from -$298000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $110.2 million in Q3 2025, with the low at -$106.9 million in Q2 2025.
- The 5-year median for Other Working Capital Changes is $421500.0 (2022), against an average of $8.6 million.
- The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes soared 1938.67% in 2023, then sank 223.22% in 2024.
- Monte Rosa Therapeutics' Other Working Capital Changes stood at -$163000.0 in 2022, then surged by 324.54% to $366000.0 in 2023, then tumbled by 223.22% to -$451000.0 in 2024, then jumped by 33.92% to -$298000.0 in 2025, then tumbled by 45.64% to -$434000.0 in 2026.
- Business Quant data shows GLUE's Other Working Capital Changes at -$434000.0 in Q1 2026, -$298000.0 in Q4 2025, and -$354000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.97 Mn |
| Jun 30, 2026 | -8.97 Mn |
| Jun 30, 2026 | -8.97 Mn |
| Mar 31, 2026 | 2.92 Mn |
| Mar 31, 2026 | 2.92 Mn |
| Mar 31, 2026 | 2.92 Mn |
| Dec 31, 2025 | -3.91 Mn |
| Dec 31, 2025 | -3.91 Mn |
| Dec 31, 2025 | -3.91 Mn |
| Sep 30, 2025 | 110.22 Mn |
| Sep 30, 2025 | 110.22 Mn |
| Sep 30, 2025 | 110.22 Mn |
| Jun 30, 2025 | -106.91 Mn |
| Jun 30, 2025 | -106.91 Mn |
| Jun 30, 2025 | -106.91 Mn |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 89.35 Mn |
| Dec 31, 2024 | 89.35 Mn |